Skip to main content
  • Explore Research
  • Learn About Clinical Trials
  • Pediatric Clinical Trials
  • Clinical Trial Video Series
  • Featured Study Opportunities
  • Find a Clinical Trial
  • Clinical Trial Patient Stories
  • Get Involved
  • Research Updates
  • Resources for Professionals
  • Newsletter Archives
  • Talk to a Specialist

Featured Study Opportunities

The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.

 

For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.

To search by state use state code:
(For e.g NY instead of New York)
To search by state use state code:
(For e.g NY instead of New York)
Clinical Trials Phases
  • Phase 2 (22)
  • Phase 3 (13)
  • Other (12)
  • Phase 1 (5)
  • Observational Study (4)
  • open label extension (3)
  • Survey (1)

Current Results: 60 entries

The PRECIOUS Study: Predicting Crohn’s & Colitis Outcomes in the United States
Observational Study
Sponsor: PredictImmune PRECIOUS Study
Description:

To demonstrate that PredictSURE IBD can stratify an ethnically diverse North American population into high and low risk based on the need for early and frequent treatment escalations in the high-risk cohort.

Recruiting Now »
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants with Moderately to Severely Active Ulcerative Colitis
Phase 2
Sponsor: Arena Pharmaceuticals Inc.
Description:

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age).

Recruiting Now »
GRAVITI: A study of an investigational study medication in participants with Moderately to Severely Active Crohn's Disease
Phase 3
Description:

The purpose of the GRAVITI Study is to evaluate the efficacy and safety of the investigational study medication in participants with moderately to severely active Crohn's disease.

Recruiting Now »
Boomerang Clinical Trial
Phase 2
Sponsor: Boomerang Medical Inc.
Description:

The objective of the Boomerang Clinical Trial is to evaluate the safety and performance of our neurostimulator medical device in patients with Crohn’s disease and left-sided ulcerative colitis and to identify patients who are most likely to benefit from treatment.

Recruiting Now »
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis: A Randomized Crossover Trial
Observational Study
Sponsor: National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
Description:

The hypothesis of this study is that the appropriate time of day of administration of oral, once-daily 5-ASA therapy in alignment with the participant’s circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels.

Recruiting Now »
Understanding Patient Decision Making in IBD-related Surgery
Other
Sponsor: Stanford Inflammatory Bowel Disease Clinic
Description:

To understand the most important priorities of IBD patients who need surgery and quantify the reasons why patients consider delaying surgery, with potential reasons including, but not limited to lack of psychosocial support, gaps in knowledge, social stigma, burden to daily life, financial reasons, concerns about fertility, and mental well-being.

Recruiting Now »
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of an Investigational Drug in participants with Moderately to Severely Active Crohn's Disease (CD): AIM-CD
Phase 2
Sponsor: AbbVie (M20 - 371)
Description:

To assess the efficacy, safety, and tolerability of the investigational drug in comparison with placebo in participants with moderately to severely active CD who had inadequate response to or were intolerant of prior biologics.

Recruiting Now »
Study to Evaluate Safety, Tolerability, and Early Efficacy of Oral E-B-FAHF-2 in Subjects with Mild-to-Moderate Crohn’s Disease
Phase 1
Sponsor: Mount Sinai Hospital - Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Description:

Primary Objective: Safety and Tolerability

Secondary Objective: Efficacy

Recruiting Now »
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease
Phase 2
Sponsor: AstraZeneca (Intrepid)
Description:

The primary goal of this study is to demonstrate the efficacy and safety of brazikumab in participants with moderately to severely active CD and demonstrate the clinical utility of a serum biomarker to identify participants who are most likely to benefit from treatment with brazikumab.

Recruiting Now »
A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION Lead-In)
Phase 2
Sponsor: AstraZeneca (Expedition)
Description:

The purpose of this study is to evaluate the efficacy and safety of brazikumab versus placebo to induce clinical remission based on endoscopic improvement, rectal bleeding, and stool frequency scores in participants with moderate to severe UC who have failed or are intolerant to conventional therapy.

Recruiting Now »

Pagination

  • Current page 1
  • Page 2
  • Next page ››
  • Last page Last »
If you are interested in listing your trial on the Featured Study Opportunities page, please contact [email protected]

The Featured Study Opportunities page is made possible in part by:

Amgen logo

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari